AP Court orders interim status quo on Sun Pharma-Ranbaxy deal: Report

30 Apr 2014 Evaluate

The Andhra Pradesh High Court has reportedly ordered an interim status quo on the $4 billion deal between Sun Pharma and Ranbaxy Laboratories. The order was in response to a petition filed by some individual investors, who alleged insider trading in Ranbaxy shares.

The petitioner is seeking action against Sun Pharma and its wholly-owned arm Silverstreet Developers LLP. Sun Pharma had earlier announced that its subsidiary’s share purchase was being annulled as part of the merger deal.

Further, the court has issued notices to SEBI, BSE, NSE, and the three companies (Sun Pharma, Silverstreet and Ranbaxy) to respond to the petitioners’ charges.

Sun Pharmaceutical Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.

Sun Pharma Inds. Share Price

1631.65 -2.75 (-0.17%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×